Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Lindmark Intestinal AB
AB
Active
Org 5591043467
Hyllie Boulevard 5 C Lgh 1602
General medical practice activities · NACE 8621
Est. 2017
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2025
SEK 130K
-62% vs 2024
EBITDA margin
62.3%
-34% vs 2024
Equity ratio
86.8%
Financial strength
Net profit 2025
SEK 291K
+7% vs 2024
EBITDA — year on year
SEK millions
1M
1M
1M
0M
0M
1M
2021
1M
0%
2022
1M
0%
2023
0M
-100%
2024
0M
0%
2025
Key figures
Annual report 2025
Revenue
SEK 130K
-62%
EBITDA
SEK 81K
-34%
Net profit
SEK 291K
+7%
Total assets
SEK 3M
-8%
Equity
SEK 2,6M
+3%
Employees
0
—
Company information
Legal name
Lindmark Intestinal AB
Org number
5591043467
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
13 mars 2017
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva hälso- och sjukvårdsverksamhet.
Contact
Address
Hyllie Boulevard 5 C Lgh 1602
Email
gudrun.lindmark@comhem.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in General medical practice activities
Companies in Malmö
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
1M
2021
1M
2022
1M
2023
0M
2024
0M
2025
EBITDA
SEK millions
0M
0M
1M
1M
1M
1M
2021
1M
2022
1M
2023
0M
2024
0M
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
941
741
1 083
341
130
Staff expenses
—
—
—
—
—
EBITDA
806
589
658
122
81
Depreciation & amort.
−0
−0
−0
−0
−0
EBIT
806
589
658
122
81
Net financials
−1
—
2
12
2
Profit before tax
605
589
811
353
372
Tax
−137
−124
−187
−80
−81
Net profit
468
465
624
273
291
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
2 894
3 090
3 488
3 208
2 967
Equity
1 718
1 995
2 424
2 492
2 574
Long-term debt
0
0
0
0
0
Short-term debt
164
83
203
74
41
Total debt
164
83
203
74
41
Financial ratios
5-year trend
EBITDA margin
62.3%
This company
15.8%
Market median
+294% vs market
2021
2025
Equity ratio
86.8%
This company
38.2%
Market median
+127% vs market
2021
2025
Return on equity
11.3%
This company
18.4%
Market median
+39% vs market
2021
2025
Net profit margin
223.8%
This company
8.1%
Market median
+2663% vs market
2021
2025
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
2021
2025
Debt / equity
0.15×
This company
0.62×
Market median
+76% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
ER
Erik Ragnar Anders Rynell
Deputy Board Member
2022
GE
Gudrun Elisabeth Lindmark
Board of Directors
2022
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Lindmark Intestinal AB also hold positions in
0
other companies.
Person
Role here
Other companies
Erik Ragnar Anders Rynell
Deputy Board Member
0 companies
Gudrun Elisabeth Lindmark
Board of Directors
0 companies